Tags

Type your tag names separated by a space and hit enter

Could pulmonary low-dose radiation therapy be an alternative treatment for patients with COVID-19 pneumonia? Preliminary results of a multicenter SEOR-GICOR nonrandomized prospective trial (IPACOVID trial).
Strahlenther Onkol. 2021 Jul 06 [Online ahead of print]SO

Abstract

PURPOSE

To evaluate the efficacy and safety of lung low-dose radiation therapy (LD-RT) for pneumonia in patients with coronavirus disease 2019 (COVID-19).

MATERIALS AND METHODS

Inclusion criteria comprised patients with COVID-19-related moderate-severe pneumonia warranting hospitalization with supplemental O2 and not candidates for admission to the intensive care unit because of comorbidities or general status. All patients received single lung dose of 0.5 Gy. Respiratory and systemic inflammatory parameters were evaluated before irradiation, at 24 h and 1 week after LD-RT. Primary endpoint was increased in the ratio of arterial oxygen partial pressure (PaO2) or the pulse oximetry saturation (SpO2) to fractional inspired oxygen (FiO2) ratio of at least 20% at 24 h with respect to the preirradiation value.

RESULTS

Between June and November 2020, 36 patients with COVID-19 pneumonia and a mean age of 84 years were enrolled. Seventeen were women and 19 were men and all of them had comorbidities. All patients had bilateral pulmonary infiltrates on chest X‑ray. All patients received dexamethasone treatment. Mean SpO2 pretreatment value was 94.28% and the SpO2/FiO2 ratio varied from 255 mm Hg to 283 mm Hg at 24 h and to 381 mm Hg at 1 week, respectively. In those who survived (23/36, 64%), a significant improvement was observed in the percentage of lung involvement in the CT scan at 1 week after LD-RT. No adverse effects related to radiation treatment have been reported.

CONCLUSIONS

LD-RT appears to be a feasible and safe option in a population with COVID-19 bilateral interstitial pneumonia in the presence of significant comorbidities.

Authors+Show Affiliations

Universitat Rovira i Virgili, Tarragona, Spain. Institut d'Investigacions Pere Virgili, Tarragona, Spain. Department of Radiation Oncology, Hospital Universitari Sant Joan de Reus, Tarragona, Spain.Department of Radiation Oncology, Hospital del Mar, Barcelona, Spain. malgara@parcdesalutmar.cat. Autonomous University of Barcelona, Barcelona, Spain. malgara@parcdesalutmar.cat. Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain. malgara@parcdesalutmar.cat.Universitat Rovira i Virgili, Tarragona, Spain. Department of Geriatric and Palliative care, Hospital Universitari Sant Joan de Reus, Tarragona, Spain.Department of Radiation Oncology, HM Hospitales., Madrid, Spain.Department of Radiation Oncology, Hospital del Mar, Barcelona, Spain. Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain. Pompeu Fabra University Barcelona, Barcelona, Spain.Department of Radiation Oncology, HM Hospitales., Madrid, Spain.Universitat Rovira i Virgili, Tarragona, Spain. Department of Geriatric and Palliative care, Hospital Universitari Sant Joan de Reus, Tarragona, Spain.Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain. Department of Critical Care, Hospital del Mar, Barcelona, Spain.Department of Medical Physics, HM Hospitales, Madrid, Spain.Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain. Department of Infection Diseases, Hospital del Mar, Barcelona, Spain.Universitat Rovira i Virgili, Tarragona, Spain. Institut d'Investigacions Pere Virgili, Tarragona, Spain. Department of Radiation Oncology, Hospital Universitari Sant Joan de Reus, Tarragona, Spain.Department of Internal Medicine, HM Hospitales, Madrid, Spain.Department of Radiation Oncology, Hospital del Mar, Barcelona, Spain. Autonomous University of Barcelona, Barcelona, Spain.Universitat Rovira i Virgili, Tarragona, Spain. Institut d'Investigacions Pere Virgili, Tarragona, Spain. Department of Radiation Oncology, Hospital Universitari Sant Joan de Reus, Tarragona, Spain.Department of Internal Medicine, HM Hospitales, Madrid, Spain.Universitat Rovira i Virgili, Tarragona, Spain. Institut d'Investigacions Pere Virgili, Tarragona, Spain. Department of Radiation Oncology, Hospital Universitari Sant Joan de Reus, Tarragona, Spain.Department of Radiation Oncology, Hospital del Mar, Barcelona, Spain. Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain. Pompeu Fabra University Barcelona, Barcelona, Spain.Universitat Rovira i Virgili, Tarragona, Spain. Institut d'Investigacions Pere Virgili, Tarragona, Spain. Department of Radiation Oncology, Hospital Universitari Sant Joan de Reus, Tarragona, Spain.Department of Radiation Oncology, HM Hospitales., Madrid, Spain.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

34230996

Citation

Arenas, M, et al. "Could Pulmonary Low-dose Radiation Therapy Be an Alternative Treatment for Patients With COVID-19 Pneumonia? Preliminary Results of a Multicenter SEOR-GICOR Nonrandomized Prospective Trial (IPACOVID Trial)." Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [et Al], 2021.
Arenas M, Algara M, De Febrer G, et al. Could pulmonary low-dose radiation therapy be an alternative treatment for patients with COVID-19 pneumonia? Preliminary results of a multicenter SEOR-GICOR nonrandomized prospective trial (IPACOVID trial). Strahlenther Onkol. 2021.
Arenas, M., Algara, M., De Febrer, G., Rubio, C., Sanz, X., de la Casa, M. A., Vasco, C., Marín, J., Fernández-Letón, P., Villar, J., Torres-Royo, L., Villares, P., Membrive, I., Acosta, J., López-Cano, M., Araguas, P., Quera, J., Rodríguez-Tomás, F., & Montero, A. (2021). Could pulmonary low-dose radiation therapy be an alternative treatment for patients with COVID-19 pneumonia? Preliminary results of a multicenter SEOR-GICOR nonrandomized prospective trial (IPACOVID trial). Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [et Al]. https://doi.org/10.1007/s00066-021-01803-3
Arenas M, et al. Could Pulmonary Low-dose Radiation Therapy Be an Alternative Treatment for Patients With COVID-19 Pneumonia? Preliminary Results of a Multicenter SEOR-GICOR Nonrandomized Prospective Trial (IPACOVID Trial). Strahlenther Onkol. 2021 Jul 6; PubMed PMID: 34230996.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Could pulmonary low-dose radiation therapy be an alternative treatment for patients with COVID-19 pneumonia? Preliminary results of a multicenter SEOR-GICOR nonrandomized prospective trial (IPACOVID trial). AU - Arenas,M, AU - Algara,M, AU - De Febrer,G, AU - Rubio,C, AU - Sanz,X, AU - de la Casa,M A, AU - Vasco,C, AU - Marín,J, AU - Fernández-Letón,P, AU - Villar,J, AU - Torres-Royo,L, AU - Villares,P, AU - Membrive,I, AU - Acosta,J, AU - López-Cano,M, AU - Araguas,P, AU - Quera,J, AU - Rodríguez-Tomás,F, AU - Montero,A, Y1 - 2021/07/06/ PY - 2021/03/01/received PY - 2021/06/01/accepted PY - 2021/7/7/entrez PY - 2021/7/8/pubmed PY - 2021/7/8/medline KW - Anti-inflammatory effects KW - COVID-19 pneumonia KW - Low-dose radiation therapy KW - Lung irradiation KW - Treatment outcome JF - Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] JO - Strahlenther Onkol N2 - PURPOSE: To evaluate the efficacy and safety of lung low-dose radiation therapy (LD-RT) for pneumonia in patients with coronavirus disease 2019 (COVID-19). MATERIALS AND METHODS: Inclusion criteria comprised patients with COVID-19-related moderate-severe pneumonia warranting hospitalization with supplemental O2 and not candidates for admission to the intensive care unit because of comorbidities or general status. All patients received single lung dose of 0.5 Gy. Respiratory and systemic inflammatory parameters were evaluated before irradiation, at 24 h and 1 week after LD-RT. Primary endpoint was increased in the ratio of arterial oxygen partial pressure (PaO2) or the pulse oximetry saturation (SpO2) to fractional inspired oxygen (FiO2) ratio of at least 20% at 24 h with respect to the preirradiation value. RESULTS: Between June and November 2020, 36 patients with COVID-19 pneumonia and a mean age of 84 years were enrolled. Seventeen were women and 19 were men and all of them had comorbidities. All patients had bilateral pulmonary infiltrates on chest X‑ray. All patients received dexamethasone treatment. Mean SpO2 pretreatment value was 94.28% and the SpO2/FiO2 ratio varied from 255 mm Hg to 283 mm Hg at 24 h and to 381 mm Hg at 1 week, respectively. In those who survived (23/36, 64%), a significant improvement was observed in the percentage of lung involvement in the CT scan at 1 week after LD-RT. No adverse effects related to radiation treatment have been reported. CONCLUSIONS: LD-RT appears to be a feasible and safe option in a population with COVID-19 bilateral interstitial pneumonia in the presence of significant comorbidities. SN - 1439-099X UR - https://www.unboundmedicine.com/medline/citation/34230996/Could_pulmonary_low-dose_radiation_therapy_be_an_alternative_treatment_for_patients_with_COVID-19_pneumonia_Preliminary_results_of_a_multicenter_SEOR-GICOR_nonrandomized_prospective_trial_(IPACOVID_trial). L2 - https://dx.doi.org/10.1007/s00066-021-01803-3 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.